Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminosalicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.96 |
| ▸ | MAPT | P10636 | 5/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | GAA | P10253 | 2/20 | 0.96 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.96 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.67 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminosalicylic Acid SCHEMBL1047422 | 1.00 | ALDH1A1 (0.96) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL6400626 | 0.98 | ALDH1A1 (0.92) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL6400637 | 0.98 | ALDH1A1 (0.92) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL3333393 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL2262 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL30337954 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL29450213 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL564092 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL11788850 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EMAPTCYP3A4GAA | |
| Aminosalicylic Acid SCHEMBL29030136 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EMAPTCYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | ALDH1A1 3168/4885KDM4E 4235/4885MAPT 4726/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | ALDH1A1 939/4885KDM4E 3462/4885MAPT 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.